Search Results - (Author, Cooperation:A. K. Stewart)
-
1Latest Papers from Table of Contents or Articles in PressStaff View
Publication Date: 2014-01-18Publisher: American Association for the Advancement of Science (AAAS)Print ISSN: 0036-8075Electronic ISSN: 1095-9203Topics: BiologyChemistry and PharmacologyComputer ScienceMedicineNatural Sciences in GeneralPhysicsKeywords: Antineoplastic Agents/*pharmacology ; Humans ; Ikaros Transcription Factor/*metabolism ; Multiple Myeloma/*metabolism ; Peptide Hydrolases/*metabolism ; Teratogens/*pharmacology ; Thalidomide/*analogs & derivatives/pharmacologyPublished by: -
2Latest Papers from Table of Contents or Articles in PressM. A. Chapman ; M. S. Lawrence ; J. J. Keats ; K. Cibulskis ; C. Sougnez ; A. C. Schinzel ; C. L. Harview ; J. P. Brunet ; G. J. Ahmann ; M. Adli ; K. C. Anderson ; K. G. Ardlie ; D. Auclair ; A. Baker ; P. L. Bergsagel ; B. E. Bernstein ; Y. Drier ; R. Fonseca ; S. B. Gabriel ; C. C. Hofmeister ; S. Jagannath ; A. J. Jakubowiak ; A. Krishnan ; J. Levy ; T. Liefeld ; S. Lonial ; S. Mahan ; B. Mfuko ; S. Monti ; L. M. Perkins ; R. Onofrio ; T. J. Pugh ; S. V. Rajkumar ; A. H. Ramos ; D. S. Siegel ; A. Sivachenko ; A. K. Stewart ; S. Trudel ; R. Vij ; D. Voet ; W. Winckler ; T. Zimmerman ; J. Carpten ; J. Trent ; W. C. Hahn ; L. A. Garraway ; M. Meyerson ; E. S. Lander ; G. Getz ; T. R. Golub
Nature Publishing Group (NPG)
Published 2011Staff ViewPublication Date: 2011-03-25Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsKeywords: Amino Acid Sequence ; Blood Coagulation/genetics ; CpG Islands/genetics ; DNA Mutational Analysis ; DNA Repair/genetics ; Exons/genetics ; Exosome Multienzyme Ribonuclease Complex ; Genome, Human/*genetics ; Genomics ; Histones/metabolism ; Homeodomain Proteins/genetics ; Homeostasis/genetics ; Humans ; Methylation ; Models, Molecular ; Molecular Sequence Data ; Multiple Myeloma/drug therapy/enzymology/*genetics/metabolism ; Mutation/*genetics ; NF-kappa B/metabolism ; Oncogenes/genetics ; Open Reading Frames/genetics ; Protein Biosynthesis/genetics ; Protein Conformation ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors/genetics/metabolism ; RNA Processing, Post-Transcriptional/genetics ; Ribonucleases/chemistry/genetics ; Signal Transduction/genetics ; Transcription, Genetic/geneticsPublished by: -
3Latest Papers from Table of Contents or Articles in PressStaff View
Publication Date: 2018-08-10Publisher: American Society of Hematology (ASH)Print ISSN: 0006-4971Electronic ISSN: 1528-0020Topics: BiologyMedicineKeywords: Lymphoid NeoplasiaPublished by: -
4Articles: DFG German National LicensesStewart, A. K. ; Huang, C. ; Long, A. A. ; Stollar, B. D. ; Schwartz, R. S.
Oxford, UK : Blackwell Publishing Ltd
Published 1992Staff ViewISSN: 1600-065XSource: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineType of Medium: Electronic ResourceURL: -
5Articles: DFG German National LicensesGirouard, C. ; Dufresne, J. ; Imrie, K. ; Stewart, A. K. ; Brandwein, J. ; Prince, H. M. ; Pantolony, D. ; Keating, A. ; Crump, M.
Springer
Published 1997Staff ViewISSN: 1569-8041Keywords: autologous BMT ; refractory lymphoma ; relapsed lymphomaSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Background: The role of intensive chemotherapy with autologous blood andmarrow transplantation (ABMT) for patients with relapsed or refractoryintermediate grade non-Hodgkin‘s lymphoma has recently been established.However, conventional dose salvage chemotherapy is frequently used todetermine chemotherapy sensitivity and reduce tumor bulk prior to intensivetherapy. Different salvage regimens have been proposed but none appearssignificantly superior. The purpose of this study was to determine theefficacy of mini-BEAM salvage chemotherapy in patients referred for ABMT andto define prognostic factors of response. Patients and methods: One hundred four patients referred forconsideration of ABMT after failure of primary anthracycline-basedchemotherapy received BCNU 60 mg/m2 day 1, etoposide 75mg/m2 day 2–5, ara-C 100 mg/m2 q12h day2–5, melphalan 30 mg/m2 day 6 (mini-BEAM) until maximumtumor reduction. Median age was 52 (range 18–65); 57% had failedto achieve a complete response (CR) to doxorubicin-based chemotherapy atdiagnosis and only 13% had a previous CR lasting 〉 12 months.Seventy-six received mini-BEAM as first salvage chemotherapy. Results: The overall response rate (RR) was 37% (95%confidence interval (CI) 28–46%) with 12 patients achieving CRand 25 achieving PR. Theresponse rate among patients treated as first salvage was 43% comparedto 20% for patients who had failed to respond to a previous salvageregimen. Only 15% of patients who failed to respond to mini-BEAMresponded to another conventional dose salvage regimen. Thirty-eight of 104patients ultimately demonstrated sufficient response to proceed to ABMT.Actuarial survival at four years is 22% for all 104 patients, and36% for those who went on to ABMT. For those who were not transplanted,four-year survival was 18%. B symptoms and tumor burden at relapse weresignificant predictors of response to mini-BEAM in multivariate analysis, andidentified a poor prognosis group of patients unlikely to be cured by thisapproach. Conclusions: Mini-BEAM does not appear to be a superior salvage regimen inthis high-risk group of relapsed or refractory NHL patients for whom ABMT wasthe ultimate treatment intention. Only one-third of patients referred for ABMTultimately proceed to transplant; alternative treatment strategies should bedeveloped for those with a low likelihood of cure by this approach.Type of Medium: Electronic ResourceURL: